We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARIS — Inclisiran, an investigational ...

ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NEW ORLEANS — Inhibition of PCSK9 synthesis via RNA ...

Instead of popping a pill every day, people might soon control “bad” LDL cholesterol by getting an injection at their doctor’s office two or three times a year. Researchers testing a new injectable ...

Longer-term follow-up of high-risk patients treated with inclisiran (Leqvio; Novartis) shows that the early reductions in LDL-cholesterol levels are sustained over several years, according to results ...

The phase 3 ORION-11 study of inclisiran sodium met all primary and secondary end points, with efficacy consistent with findings from phase 1 and 2 studies, The Medicines Company announced today ORION ...

HealthDay News — A new injectable medication called inclisiran cuts low-density lipoprotein (LDL) cholesterol by half or more, and the effect could last for four to six months, according to research ...

Three phase 3 trials of the novel small-interfering RNA (siRNA) agent inclisiran (The Medicines Company) have been published, all showing an approximate halving of LDL cholesterol levels with the drug ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...

Share on Pinterest The newly approved drug could save thousands of lives in the U.K. alone. Coolpicture/Getty Images About half of the U.K.’s adult population currently has cholesterol levels above ...

Inclisiran lowers low-density lipoprotein (LDL; 'bad') cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol. Inclisiran lowers low-density lipoprotein ...